HF 4852Minnesota
Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.
In committee
Apr 7, 2026: Introduction and first reading, referred to Health Finance and Policy